<DOC>
	<DOCNO>NCT02570282</DOCNO>
	<brief_summary>This Phase 2 , single center , single-dose , double-blind , placebo-controlled , 2-way crossover study evaluate safety efficacy SST-6007 woman FSAD . A sufficient number participant enrol yield 30 ( approximately 15 pre-menopausal 15 post-menopausal ) participants complete SST-6007/Placebo Double-Blind , Dosing Phase study ( Visit 2 Visit 3 ) .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety SST-6007 , Topical Sildenafil Cream , Compared Placebo Women With Female Sexual Arousal Disorder</brief_title>
	<detailed_description>Participants first complete telephone screen ( &lt; 28 day prior Visit 1 , Medical Screening ) schedule Visit 1 eligible . After consent obtain , study participant undergo Visit 1 local gynecology clinic determine eligibility continue study participation . If participant meet inclusion criterion none exclusion criterion , schedule Visit 2 Visit 3 SST-6007/Placebo Double-Blind , Dosing Phase conduct Sexual Psychophysiology Laboratory University Texas Austin . Visit 2 must within 5 ( ±2 ) day Visit 1 . One visit evaluate participant 's response SST-6007 evaluate participant 's response placebo cream , use VPP , Arousometer , neutral-erotic film presentation . The sequence dose randomly assign ( i.e. , placebo cream SST-6007 SST-6007 placebo cream ) accord computer-generated , randomization . There 4-8 day washout period Visits 2 3 . During experimental session , physiological subjective sexual arousal assess simultaneously continuously use VPP Arousometer . Electrical activity heart assess ECG . ECG data use process VPA data . Immediately follow completion erotic film , subjective sexual arousal , subjective perception genital arousal , positive negative affect evaluate use self-report 7-point Likert Scale ( Film Scale ) Positive Negative Affect Schedule ( PANAS ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Sexual Dysfunctions , Psychological</mesh_term>
	<mesh_term>Sexual Dysfunction , Physiological</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1 . Postmenopausal woman ( surgically induce natural ) must meet 1 follow criterion : Surgical oophorectomy , partial hysterectomy , full hysterectomy least 1 year prior screening ( selfreport ) . No spontaneous menses &gt; 1 year ( selfreport ) . 2 . Postmenopausal participant , hormone replacement therapy ( HRT ) , must serum folliclestimulating hormone ( FSH ) lab result &gt; 40mIU/mL . 3 . Women childbearing potential must agree continue use appropriate form birth control Visit 1 7 day follow completion Visit 3 . Acceptable form birth control include use IUD hormonal therapy ( oral , patch , etc. ) . Contraceptive foams/gels condom consider acceptable method birth control study . Participants must stable dose least 6 month prior Visit 1 . 4 . Participant body mass index ( BMI ) 18 30 kg/m² , inclusive . 5 . Participant heterosexual . 6 . Participant normal electrocardiogram Visit 1 . 7 . Participant capable understand comply protocol agree sign informed consent document . 8 . Participant must agree use vaginal vulvar lubricant , spermicide , cream gel , contraceptive foam vaginal douche product Visit 1 completion Visit 3 9 Participant agree engage strenuous , unaccustomed exercise within 6 hour visit 2 visit 3 . 1 . Participant nursing pregnant ( base positive serum pregnancy test ) , wish become pregnant study period . 2 . Participant disorder history disorder may prevent successful completion study opinion SubInvestigator . 3 . Participant use topical hormone replacement therapy ( HRT ) apply locally genitals past three month . Oral patch form HRT acceptable , long participant report stable dose least 6 month prior Visit 1 . 4 . Participant significant cardiovascular , hepatic , metabolic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , genitourinary , psychiatric disease unstable medical condition would contraindicate administration study medication , interfere study evaluation , limit study participation , confound interpretation study result opinion SubInvestigator . 5 . Participant active ulcer clinically significant bleed disorder . 6 . Participant history myocardial infarction , stroke , lifethreatening arrhythmia within 6 month prior Visit 1 ; history coronary disease cause angina ; congestive heart failure require medical intervention . 7 . Participant retinitis pigmentosa sickle cell anemia related anemia , even participant feel clinically well time Visit 1 . Participants retinitis pigmentosa identify specifically ask whether condition , visual sign symptom condition ( include question participant whether difficulty see night low light , visual field deficit indicate loss peripheral central vision ) , family history . 8 Participant history orthostatic hypotension orthostatic hypotension present Visit 1 , define drop systolic blood pressure ≥ 20 mm Hg , drop diastolic blood pressure ≥ 10 mm Hg experience lightheadedness dizziness 1 3 minute change position supine standing . 9 . Participant primary anorgasmia , vaginismus , sexual aversion disorder . 10 . Participant dyspareunia . 11 . Participant type 1 type 2 diabetes . 12 . Participant undergone major pelvic surgery may cause nerve damage , include , vulvectomy , colostomy , cystostomy , serious bladder , rectal , abdominal surgery ; neurological impairment due diabetes , stroke , pelvic nerve damage secondary trauma , cancer treatment , myasthenia gravis , multiple sclerosis spinal cord damage . 13 . Participant current and/or previous report diagnosis DSMIVTR axis I disorder include organic mental syndrome disorder ( e.g. , schizophrenia , bipolar disorder , depression ) . 14 . Participant history cancer , basal cell carcinoma . 15 . Participant surgical medical condition may interfere absorption , distribution , metabolism , excretion test article opinion SubInvestigator . 16 . Participant history nonarteritic ischemic optic neuropathy ( NAION ) . 17 . Participant positive finding urine drug screen ( e.g. , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , methadone , opiates ) . 18 . Participant positive serologic finding sexually transmit infection ( syphilis , gonorrhea , chlamydia ) , human immunodeficiency virus ( HIV ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody . 19 . Participant moderate severe current vaginitis , vaginal infection include bacterial vaginosis yeast infection . The diagnosis yeast infection make SubInvestigator base physical gynecological exam ; objective exclude woman symptomatic . If woman complain symptom SubInvestigator observe discharge , vaginal wet mount test also perform confirm diagnosis yeast infection .</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Female</keyword>
</DOC>